Treatment of chronic urticaria with an inhibitor of complement activation (cinnarizine).
Twenty-three patients with chronic urticaria were treated with cinnarizine, dexchlorpheniramine and placebo in a double-blind, crossover trial. Compared to placebo treatment both cinnarizine and dexchlorpheniramine caused a statistically significant improvement in the clinical symptoms (p less than 0.01). The two active drugs were found to be equally effective; however, cinnarizine was better tolerated. Both drugs appear to be useful in the treatment of chronic urticaria.
D000328:Adult; D000368:Aged; D002744:Chlorpheniramine / Q000009:adverse effects / Q000627:therapeutic use; D002908:Chronic Disease; D002936:Cinnarizine / Q000009:adverse effects / Q000627:therapeutic use*; D003171:Complement Pathway, Classical; D003165:Complement System Proteins / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010919:Placebos / Q000627:therapeutic use; D014581:Urticaria / Q000188:drug therapy*
D010879:Piperazines; D010919:Placebos; D002936:Cinnarizine; D002744:Chlorpheniramine; D003165:Complement System Proteins